PMID- 29560123
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 9
IP  - 16
DP  - 2018 Feb 27
TI  - MET amplification assessed using optimized FISH reporting criteria predicts early 
      distant metastasis in patients with non-small cell lung cancer.
PG  - 12959-12970
LID - 10.18632/oncotarget.24430 [doi]
AB  - To investigate the prognostic impact of MET copy number (MET-CN) in patients with 
      non-small cell lung cancer (NSCLC), we retrospectively reviewed clinical and 
      pathologic data of NSCLC patients whose tumors were assessed for MET-CN using 
      fluorescence in situ hybridization (FISH). We correlated MET-CN status with 
      patient overall survival (OS) and optimized MET-FISH reporting criteria. The 
      study group included 384 patients with NSCLC of which 88% were adenocarcinoma and 
      55.7% of patients had distant metastases. There were 170 patients with stages 
      I-III and 214 patients with stage IV disease. Based on the MET-CN and MET/CEP7 
      ratio the patients were classified into 3 categories: MET-amplification (METamp): 
      MET/CEP7 >/= 2 or MET-CN >/= 5; MET-CN-gain (METcng): MET-CN >/= 4 to < 5; and 
      MET-negative (METneg): MET-CN < 4. METamp was associated with high fatality 
      (P=.036) and stage IV tumors (P=.038). In patients with stages I-III NSCLC, 
      patients in the METamp category had the shortest OS (P=.015) and more often 
      developed distant metastases within 1 year (P=.004). In patients with stage IV 
      tumors, METamp did not further impact the OS. Patients in the METcng category had 
      the longest OS (P=.053). Multivariate analysis confirmed METamp to be an 
      independent high-risk factor (HR 3.26; P=.026) and predicted earlier progression 
      to distant metastasis (HR 4.86; P=.001). In conclusion, we suggest that the 
      MET-FISH criteria presented optimizes risk stratification by defining 3 
      categories of NSCLC patients. METamp is an independent risk factor predicting 
      early distant metastasis and patients with METcng could represent a lower-risk 
      group.
FAU - Fang, Lianghua
AU  - Fang L
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
AD  - Department of Oncology, Jiangsu Province Hospital of Traditional Chinese 
      Medicine, Nanjing, Jiangsu, China.
FAU - Chen, Hui
AU  - Chen H
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Tang, Zhenya
AU  - Tang Z
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Kalhor, Neda
AU  - Kalhor N
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Liu, Ching-Hua
AU  - Liu CH
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
AD  - Department of Pathology, Northwestern University Feinberg School of Medicine, 
      Chicago, IL, USA.
FAU - Yao, Hui
AU  - Yao H
AD  - Department of Bioinformatics and Computational Biology, The University of Texas 
      MD Anderson Cancer Center, Houston, TX, USA.
FAU - Hu, Shimin
AU  - Hu S
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Lin, Pei
AU  - Lin P
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Zhao, Jin
AU  - Zhao J
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
AD  - Department of Clinical Laboratory, Hunan Cancer Hospital & The Affiliated Cancer 
      Hospital of Xiangya School of Medicine, Central South University, Changsha, 
      Hunan, China.
FAU - Luthra, Raja
AU  - Luthra R
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Singh, Rajesh R
AU  - Singh RR
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Routbort, Mark J
AU  - Routbort MJ
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Hong, David
AU  - Hong D
AD  - Department of Investigational Cancer Therapeutics, The University of Texas MD 
      Anderson Cancer Center, Houston, TX, USA.
FAU - Medeiros, L Jeffrey
AU  - Medeiros LJ
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Lu, Xinyan
AU  - Lu X
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
AD  - Department of Pathology, Northwestern University Feinberg School of Medicine, 
      Chicago, IL, USA.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20180207
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5849187
OTO - NOTNLM
OT  - MET FISH reporting criteria
OT  - MET gene amplification
OT  - distant metastasis
OT  - non-small cell lung cancer
COIS- CONFLICTS OF INTEREST The authors declare no conflicts of interest.
EDAT- 2018/03/22 06:00
MHDA- 2018/03/22 06:01
PMCR- 2018/02/27
CRDT- 2018/03/22 06:00
PHST- 2017/07/02 00:00 [received]
PHST- 2018/01/30 00:00 [accepted]
PHST- 2018/03/22 06:00 [entrez]
PHST- 2018/03/22 06:00 [pubmed]
PHST- 2018/03/22 06:01 [medline]
PHST- 2018/02/27 00:00 [pmc-release]
AID - 24430 [pii]
AID - 10.18632/oncotarget.24430 [doi]
PST - epublish
SO  - Oncotarget. 2018 Feb 7;9(16):12959-12970. doi: 10.18632/oncotarget.24430. 
      eCollection 2018 Feb 27.